Fig. 5. VWF:RCO can be automated by replacing platelets of the original VWF:RCO with microparticles. In the method developed by Werfen, ristocetin primed plasma VWF binds glycocalicin. The bound glycocalicin molecules can be detected by anti-glycocalicin-coated microparticles (A). Alternatively, the glycocalicin with a GOF mutation of platelet type VWD can be used without ristocetin, as for the reagent from Siemens (B).

© Blood Research